Influenza Vaccine Market Share

The region influenza vaccine market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The rapid spread of the influenza A virus among the population, new product launches, and expansion of services for product distribution. As per the data by CDC, in 2022, the United States reported seven cases of human infections with novel variants of influenza A viruses. This included 3 H3N2v and 4 H1N2v viruses. Moreover, the development of innovative products and increasing initiatives towards influenza vaccination coupled with the advanced technological vaccine manufacturing process in North America is anticipated to drive the regional market in the coming years.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of influenza vaccine is estimated at USD 7.32 billion.

The influenza vaccine market size was over USD 6.92 billion in 2024 and is poised to cross USD 17.01 billion by the end of 2037, growing at more than 7.1% CAGR during the forecast period i.e., between 2025-2037. Rapid spread of influenza virus, rising COVID-19 cases, increasing healthcare spending along with incidence of chronic diseases among people will boost the market growth.

North America industry is projected to hold majority revenue share by 2037, impelled by rapid spread of the influenza A virus among the population, new product launches, and expansion of services for product distribution in the region.

The major players in the market include BioDiem Ltd., SANOFI, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Sinovac Biotech Ltd., Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., CSL Limited, Johnson & Johnson Services, Inc., Astellas Pharma Inc.

Influenza Vaccine Market Share